Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 3/20 | 0.43 |
| ▸ | CDK8 | P49336 | 3/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | TRPC6 | Q9Y210 | 11/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13467180 | 0.78 | CCNC (0.50) | GABRA1CCNCCDK8CDK19RIPK1 | |
| SCHEMBL12425603 | 0.77 | CHRNA4 (0.40) | TRPC6SCD5SCD | |
| SCHEMBL25747708 | 0.76 | GABRA1 (0.44) | GABRA1CCNCCDK8CDK19SCD5 | |
| SCHEMBL30351058 | 0.76 | GABRA1 (0.44) | GABRA1CCNCCDK8CDK19SCD5 | |
| SCHEMBL20929521 | 0.74 | NPC1 (0.49) | — | |
| SCHEMBL16131994 | 0.73 | PDE10A (0.53) | GABRA1CCNCCDK8CDK19RIPK1 | |
| SCHEMBL31150452 | 0.73 | GABRA1 (0.38) | GABRA1CCNCCDK8CDK19RIPK1 | |
| SCHEMBL25319219 | 0.73 | GABRA1 (0.38) | GABRA1CCNCCDK8CDK19RIPK1 | |
| SCHEMBL25747706 | 0.72 | GABRA1 (0.42) | GABRA1CCNCCDK8CDK19SCD5 | |
| SCHEMBL2550739 | 0.71 | SIRT6 (0.44) | GABRA1CCNCCDK8CDK19RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118591534-A | Novel benzimidazole pyridine derivatives | 豪夫迈·罗氏有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | GABRA1 329/4885CCNC 562/4885CDK8 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.